share_log

10-Q: Q2 2024 Earnings Report

10-Q: Q2 2024 Earnings Report

10-Q：2024财年二季报
美股SEC公告 ·  2024/08/15 03:35

Moomoo AI 已提取核心信息

Aclarion reported Q2 2024 financial results with revenue of $10,971, down 36% year-over-year from $17,072, primarily due to concluded clinical activities. The company ended the quarter with a cash balance of $1.2 million. Gross loss was $12,323 compared to a loss of $2,229 in Q2 2023, while operating expenses decreased 20% to $1.1 million.The company completed significant financing activities in early 2024, including a $3.0 million public offering in February and raising approximately $1.7 million through an equity line agreement. Operating expenses were reduced through lower personnel costs, D&O insurance premiums, and legal fees, though partially offset by increased investor relations and clinical trial investments.Management indicates current cash will fund operations into Q3 2024, approaching the September 2024 maturity of their unsecured note. The company will need to raise additional capital to continue funding technology development, with plans to secure such funding. Total liabilities decreased to $1.4 million as of June 30, 2024, from $3.2 million at year-end 2023.
Aclarion reported Q2 2024 financial results with revenue of $10,971, down 36% year-over-year from $17,072, primarily due to concluded clinical activities. The company ended the quarter with a cash balance of $1.2 million. Gross loss was $12,323 compared to a loss of $2,229 in Q2 2023, while operating expenses decreased 20% to $1.1 million.The company completed significant financing activities in early 2024, including a $3.0 million public offering in February and raising approximately $1.7 million through an equity line agreement. Operating expenses were reduced through lower personnel costs, D&O insurance premiums, and legal fees, though partially offset by increased investor relations and clinical trial investments.Management indicates current cash will fund operations into Q3 2024, approaching the September 2024 maturity of their unsecured note. The company will need to raise additional capital to continue funding technology development, with plans to secure such funding. Total liabilities decreased to $1.4 million as of June 30, 2024, from $3.2 million at year-end 2023.
Aclarion报告了2024年第二季度的财务结果，营业收入为10,971美元，同比下降36%，去年同期为17,072美元，主要由于临床活动的结束。公司在本季度末的现金余额为120万美元。毛亏损为12,323美元，而2023年第二季度的亏损为2,229美元，营业费用降低了20%，至110万美元。公司在2024年初完成了重大的融资活动，包括在2月份进行的300万美元的公开发行，以及通过股权融资协议筹集的约170万美元。营业费用通过降低人事成本、D&O保险费和法律费用得以减少，尽管部分被增加的投资者关系和临床试验投资所抵消。管理层表示，目前的现金将支持运营直到2024年第三季度，接近2024年9月到期的无担保票据。为了继续资助科技开发，公司需要筹集额外的资金，并计划确保这些资金。至2024年6月30日，总负债从2023年年底的320万美元减少至140万美元。
Aclarion报告了2024年第二季度的财务结果，营业收入为10,971美元，同比下降36%，去年同期为17,072美元，主要由于临床活动的结束。公司在本季度末的现金余额为120万美元。毛亏损为12,323美元，而2023年第二季度的亏损为2,229美元，营业费用降低了20%，至110万美元。公司在2024年初完成了重大的融资活动，包括在2月份进行的300万美元的公开发行，以及通过股权融资协议筹集的约170万美元。营业费用通过降低人事成本、D&O保险费和法律费用得以减少，尽管部分被增加的投资者关系和临床试验投资所抵消。管理层表示，目前的现金将支持运营直到2024年第三季度，接近2024年9月到期的无担保票据。为了继续资助科技开发，公司需要筹集额外的资金，并计划确保这些资金。至2024年6月30日，总负债从2023年年底的320万美元减少至140万美元。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间